Depending on where you live, spring is here—or at least on its way. It’s the time of year to thaw out along with the trees, grass, and flowers. With spring comes our promise to get ourselves into shape for the summer, and life gets busier with more outdoor activities for the whole family.
OSD is of significant concern in patients with glaucoma on multiple topical medications. Optimal treatment of this condition with minimizing the intensity as well as with additional pharmacologic treatments for OSD can improve visual acuity and compliance and result in better outcomes both medically and regarding patient satisfaction.
The advent of low-risk surgical options is moving glaucoma from a pharmaceutically managed disease to one controlled via a series of surgical procedures. The outcome appears to be highly beneficial for patients, says Robert J. Noecker, MD.
Treating diabetic macular edema (DME) has evolved from the ETDRS-style focal/grid laser being the standard of care since 1985 to the modern era of pharmacotherapy—with anti-vascular endothelial growth factor (VEGF) injections now taking center stage as primary treatment for most patients.
Patients don’t have to wait for 2020 to achieve 20/20 vision at near without spectacles or contact lenses. Rather, the advancements we have seen just in the past few years should be enough to help manage their expectations.
America may face a public health crisis in coming years unless drastic changes are not made to the public perception of eye health, according to a report from the National Academies of Sciences, Engineering, and Medicine (NASEM). Taking steps to create a public conversation about the matter, Allergan has launched a public awareness campaign, See America, to improve this awareness of and access to comprehensive eye exams.